beast_Medium resized

Immunotherapy: have we unleashed the beast?

Immunotherapy is beyond a shadow of a doubt the most popular topic among cancer experts. Specialist press coverage on the most recent clinical trial results has been accompanied by an unprecedented social media buzz that has contributed to the maturation of a collective view of immunotherapy as the treatment set to revolutionize cancer therapy.


A Novel Hypoxia Activated EGFR Inhibitor Kills Two Birds with One Stone Bringing Hope for Resistant Lung Cancer

Misregulation of the epidermal growth factor receptor (EGFR) gene is a common theme in cancer biology and consistent efforts have been made to identify the underlying mutations driving tumorigenesis. However some forms of cancer retain one normal copy of EGFR, suggesting the existence of a more general physiological trigger for EGFR aberrant activation. A recent… Read more »